About Monoclonal Antibodies
Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell. They are complex proteins with high molecular weight, and were first developed in 1975 by Kohler and Milstein.
Technavio’s analysts forecast the global monoclonal antibodies (mAbs) market to grow at a CAGR of 9.84% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded mAbs and biosimilars used to treat cancer, autoimmune and inflammatory diseases, respiratory diseases, and ophthalmology. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market, along with the decline in revenues from the patent expiries of the marketed drugs, during the forecast period.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Monoclonal Antibodies (mAbs) Market 2016-2020
Technavio recognizes the following companies as the key players in the global monoclonal antibodies (mAbs) market: AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, and Merck.
Other Prominent Vendors in the market are: AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “The emergence of biosimilars will be a key trend leading to the market growth. In recent years, the population of the aging has increased due to the availability of advanced medical care. This rising aging population has also increased the prevalence of various chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers and metabolic disorders, leading to a high demand for quality care. Biosimilars will likely play a prominent role in this scenario.”
According to the report, one of the key drivers for market growth will be special regulatory drug designations. The US FDA's Office of Orphan Products Development (OOPD) aims to develop and evaluate drugs, biologics, and devices that effectively treat and diagnose rare diseases or conditions, and provides incentives to companies that develop drugs for rare disorders. It also grants orphan status to drugs and biologics proven to be effective and safe in treating rare diseases.
Further, the report states that threat from chemotherapy and off-label drugs will be one of the challenges faced by the market. Cytotoxic chemotherapy is used by physicians worldwide to treat cancer. Chemotherapy drugs most often used to treat cancer are chlorambucil, fludarabine, cyclophosphamide, and bendamustine. Fludarabine is administered in combination with cyclophosphamide (a fixed combination (FC) regimen). In some cases, rituximab is also given along with the FC regimen. Sometimes, a combination of chemotherapy drugs is administered. Off-label drug use is frequently seen in treating cancers, inflammatory diseases, and respiratory diseases.
AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Merck, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, UCB.